搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
12 天
on MSN
Gilead Licenses Long-Acting HIV Prevention Drug to Generics Firms
Gilead Sciences Inc. said it is licensing its twice-yearly experimental HIV prevention drug lenacapavir to six generics ...
Daily Maverick on MSN
19 小时
Efficacy of six-monthly HIV prevention jab confirmed in second major study
In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...
FiercePharma
12 天
Gilead strikes licensing deals with 6 generics makers to boost access to long-acting HIV ...
Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV ...
3 天
Gilead's HIV Prevention Treatment Lenacapavir Shows Potential
GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted ...
12 天
Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries
Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell ...
BioSpace
11 天
Gilead Partners With Generics Developers to Provide HIV Drug to Low-Income Countries
Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for ...
CSR Wire
5 天
Gilead Sciences: New Report Shows Every Country in the World Must Do More To End the HIV ...
Despite major advances in scientific innovation, access to care and growth of health systems, there are still millions of ...
STAT
12 天
Gilead strikes voluntary licensing deals in poor countries for its pricey HIV drug
Gilead will license the HIV drug lenacapavir, a twice-yearly injectable, to six generic makers for 120 countries.
12 天
Gilead strikes deal to rush HIV prevention drug to countries most in need
Why Gilead cut a deal with 6 generics companies around a yet-to-be-approved, twice-a-year HIV PrEP drug: "It really is all ...
Yahoo Finance
7 天
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at ...
October 07, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq ... the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and ...
7 天
Gilead Sciences : Phase 3 Data Shows 96% Reduction In HIV Infections With Lenacapavir
Gilead Sciences Inc. (GILD) announced that additional data from its pivotal Phase 3 PURPOSE 2 trial demonstrated a 96% reduction in ...
emjreviews.com
11 天
Gilead expands access to PrEP HIV candidate in 120 countries
A new licensing agreement from Gilead Sciences and six generic drug manufacturers is poised to transform HIV prevention ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈